Mountain View Pharmaceuticals, Inc. Receives European Patent on Potential Long-Acting Drug for Multiple Sclerosis
6/11/2012 9:53:49 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of European Patent No. 1 667 708 B1, titled “Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency.” The conjugates covered by this patent could enable less frequent and better tolerated dosing of one of the most widely used treatments worldwide for relapsing-remitting multiple sclerosis, interferon-beta-1b.
comments powered by